AGM Presentation
Released
Released
Announcement PDF
0
RCE Corporate
Presentation
Annual General Meeting 2025
ASX:RCE | FSE:R9Q
November 2025
Disclaimer
DISCLAIMER
This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does
not purport to contain all the information that a prospective investor may require in connection
with any
potential investment in the Company. You should not treat the contents of this presentation,
or any information provided in connection with it, as financial advice, financial product advice
or advice relating to legal, taxation or investment matters.
No representation or warranty (whether express or implied) is made by the Company or any
of its officers, advisers, agents or employees as to the accuracy, completeness or
reasonableness of the information, statements, opinions or matters (express or implied)
arising out of, contained in or derived from this presentation or provided in connection with it,
or any omission from this presentation, nor as to the attainability of any estimates, forecasts
or projections set out in this presentation.
This presentation is provided expressly on the basis that you will carry out your own
independent inquiries into the matters contained in the presentation and make your own
independent decisions about the affairs, financial position or prospects of the Company. The
Company reserves the right to update, amend or supplement the information at any time in its
absolute discretion (without incurring any obligation to do so).
Neither the Company, nor its related bodies corporate, officers, their advisers, agents and
employees accept any responsibility or liability to you or to any other person or entity arising
out of this presentation including pursuant to the general law (whether for negligence, under
statute or otherwise), or under the Australian Securities and Investments Commission Act
2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding
provision of any Australian state or territory legislation (or the law of any similar legislation in
any other jurisdiction), or similar provision under any applicable law. Any such responsibility or
liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.
Nothing in this material should be construed as either an offer to sell or a solicitation of an
offer to buy or sell securities. It does not include all available information and should not be
used in isolation as a basis to invest in the Company.
1
FUTURE MATTERS
This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of
the Company.
Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are
based on certain assumptions, which may not be met or on which views may differ and may be affected by
known and unknown risks. The performance and operations of the Company may be influenced by a number of
factors, many of which are outside the control of the Company. No representation or warranty, express or
implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any
intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will
be achieved.
Given the risks and uncertainties that may cause the Company’s actual future results, performance or
achievements to be materially different from those expected, planned or intended, recipients should not place
undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not
warrant or represent that the actual results, performance or achievements will be as expected, planned or
intended.
US DISCLOSURE
This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any
securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S
under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be,
registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States,
and may not be offered or sold in the United States or to any US person without being so registered or
pursuant to an exemption from registration including an exemption for qualified institutional buyers.
Recce Pharmaceuticals – Company Overview
• Publicly-traded on the Australian and Frankfurt exchanges – (ASX: RCE, FSE: R9Q).
• Therapeutics to address the global healthcare crisis of antibiotic resistance: works
faster than traditional antibiotics and against multidrug-resistant bacteria.
• Phase 3 Clinical trial (Indonesia) – patient dosing commenced.
• Multiple successful Phase I and Phase II clinical trials across Australia.
• US Defense Burn Research Program grant; US Army Medical Research Institute of
Infectious Diseases – in progress.
• >40 granted patents across major pharmaceutical markets out to 2041.
• Our goal is for our product to be made available in Indonesia in 2026.
An Australian clinical-stage biotech with a United States presence, developing a New Class of Synthetic Anti-infectives with a
unique mechanism of action for a broad spectrum of infections including serious/life-threatening indications.
RECCE® 327 granted Qualified Infectious Disease Product (QIDP)
Designation by U.S. Food and Drug Administration giving 10 years
market exclusivity plus fast-track approval.
RECCE®327 added to World Health Organization’s List
of Antibacterial Products in Clinical Development.
2
Board and Management Structure
3
Dr John Prendergast – Chairman
BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU)
US-based biotechnology executive and investor with extensive experience in the
commercialisation, financing, and sale of pharmaceutical assets. He has
overseen three New Drug Approvals and led multiple licensing and M&A
transactions, including the successful sale of Vyleesi® to Cosette
Pharmaceuticals for USD $159 million in contingent, sales-based milestones.
Over his career, he has been instrumental in capital raises exceeding USD $1
billion and has directed numerous transactions involving the sale of assets,
technologies, and companies across the biotechnology and healthcare sectors.
James Graham – Managing Director & Chief Executive Officer
BCom (Entrepreneurship), GAICD
Mr Graham is the Chief Executive Officer of Recce Pharmaceuticals. He brings
extensive experience in marketing, business development, and the
commercialisation of early-stage technologies with global potential. With a
proven track record of growing globally focused companies, Mr Graham has
applied his expertise to Recce, including serving on its Board of Directors. He
has participated in nearly every capital raise to date, demonstrating a strong
commitment to expanding Recce’s commercial opportunities and clinical
programs.
Dr Alan Dunton – Chief Medical Advisor & Non-Executive Director
BSc (BioChem) Hons, M.D. (NYU)
US-based pharmaceutical executive with more than 30 years of experience in
drug development and commercial leadership. Former President and Managing
Director of Janssen Research Foundation (Johnson & Johnson), he directed the
approval and launch of around 20 New Drug Applications, including Levaquin®,
Regranex®, Aleve®, Procrit®, Sporanox®, Reminyl® and Risperdal®. He has
held senior roles at Roche, CIBA-GEIGY, Syntex and Purdue Pharma, and
served as CEO of Panacos, Metaphore and EpiCept Pharmaceuticals,
overseeing multiple corporate transactions and the successful sale of Vyleesi®
to Cosette Pharmaceuticals for USD $159 million in contingent, sales-based
milestones.
Michele Dilizia – Executive Director & Chief Scientific Officer
BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM
Co-inventor and qualified medical scientist with a specialisation in medical
microbiology and regulatory affairs. Ms Dilizia successfully co-led the
research and development of Recce’s suite of anti- infective
compounds, resulting in a portfolio of granted patents across the globe,
including a Qualified Infectious Disease Product designation with the U.S.
FDA.
Dr Justin Ward – Executive Director & Principal Quality Chemist
BSc (Chem), PhD (Chem), M Pharm, MRACI, CChem
A quality control expert who has worked with leading pharmaceutical
companies. He previously held a technical role with Pfizer, involving providing
data for the regulatory submissions to the FDA and TGA. Dr Ward is bringing
Recce’s research and development and manufacturing up to US FDA
requirements.
Alistair McKeough – Non-Executive Director
Mr McKeough is an experienced executive and solicitor. Before being
appointed as a non-executive director in 2022, Alistair served as Recce’s
company secretary and he has been involved with the company since 2017.
Alistair has extensive experience in a variety of private and listed corporations
across many sectors, including professional services, technology, financial
services, charities, health, biotech, childcare and education. Recent roles
include Managing Director of a legal practice specialising in equity capital
markets and advice to listed companies and as part of the senior leadership
team at share registry, Automic Group.
recce.com.au
World Health Organization added RECCE® compounds to its list of antibacterial products in
clinical development for priority pathogens
US FDA Qualified Infectious Disease Product designation provides 10 years of market
exclusivity plus fast-track approval*
Multiple clinical indications and formulations in Phase I and II addressing unmet medical
needs
Leading, Australian Anti-Infective Company
Near-term commercialisation pathway expected to launch in 2026
Products address the global healthcare crisis of antibiotic resistance
Phase 3 in Indonesia of lead asset RECCE® 327 Gel for the treatment of Diabetic Foot
Infections – Expected launch in 2026 and opens gateway to ASEAN and other markets
*Awarded by the US FDA in 2017 for R327 bacteraemia (broad-spectrum bacterial sepsis). Time starts only from potential market approval
4
recce.com.au
Company Overview
Capital Structure – October 2025
ASX & FSE Code RCE, R9Q
Share Price AUD $0.405
3-Month Daily Average
Daily Volume
114.94k
Shares on Issue 289.18 million
Unlisted Options (Avg $1.087) 24.17 million
Market Capitalisation AUD $121.46 million
Top 20 Shareholders 53.64%
RCE Share Price and Volume Chart – 12 Months (price shown in AUD)
Australian Government awarded AUD
$54,947,284 (USD $37,043,433) Advanced
Overseas Finding across RCE infectious
disease portfolio*
Multiple clinical indications and formulations
in Phase I and Phase II addressing unmet
medical needs: Sepsis, UTI/Urosepsis,
Burn Wounds and ABSSSI, including
Diabetic Foot Infections
Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of novel synthetic anti-infectives
Volume Close $
*The Advanced Finding is a binding, underwritten guarantee provided by the Australian Government, which affirms the Company’s R&D activities are of national interest and extends the 43.5% R&D rebate from locally, to cover those undertaken by the Company anywhere in the world for a period of
three years. This finding does not constitute a grant, or an upfront payment of the amount awarded
Proprietary first-in-class, broad-
spectrum anti-infectives
against bacteria
I.V. and topical treatments advancing for
UTI/Urosepsis and Acute Bacterial Skin and Skin
Structure Infections (ABSSSI) including DFI; as well
as US Department of Defense Burn Wound Program
and Indonesian clinical trials for topical treatments.
*Non-Dilutive Financing via debt facility of up to ~A$30 million with Avenue
Capital Group.
5
$-
$0.10
$0.20
$0.30
$0.40
$0.50
$0.60
-
500,000
1,000,000
1,500,000
2,000,000
2,500,000
3,000,000
ExecutiveOverview
Currently only 6 companies on the ASX are conducting Phase III therapeutic trials
6
5.44B
3.22B
2.75B
821M
306M
180M
123M
98M
72M
** Not started or failed ** A medical device
• Telix Pharmaceuticals (ASX: TLX)
• Mesoblast (ASX: MSB)
• Neuren Pharmaceuticals (ASX: NEU)
• Opthea (ASX: OPT) **
• Dimerix (ASX: DXB)
• Paradigm Biopharmaceuticals (ASX: PAR)
• Recce Pharmaceuticals (ASX: RCE)
• Avita Medical (ASX: AVH) **
• Amplia Therapeutics (ASX: ATX) **
Significant potential for value
creation in next 12-18mos
recce.com.au
Synthetic Anti-Infectives
The need for a new class of antibiotics
On-track to be the only global clinical stage company whose drug is
shown to be efficacious against the full suite of ESKAPE pathogens
NO pre-formed natural
superbugs
Very broad-spectrum coverage
of bacteria with no signs of
resistance
Universal Mechanism of Action
- does not succumb to
resistance
Unprecedented, broad-
spectrum activity against Gram
+ve and Gram -ve bacteria and maintains
its activity even with repeated use
Extremely rapid onset of effect –
measured in minutes as
compared to hours for typical
antibiotics
Multiple formulations
available – intravenous, topical
liquid, topical gel and aerosol
for inhalation or intranasal
7
Since Last AGM – Clinical Trial Progress
8
ALL Objectives Achieved
from last AGM
New Objectives for 2025/2026
✓ Phase II Clinical Trial data successfully
demonstrated R327G achieving a 93%
primary efficacy endpoint over 14-days,
meeting all study endpoints.
✓ Phase II Clinical Trial receives approval
for additional diabetic patients to be
treated with R327G.
Phase II ABSSSI
Clinical Trial
Topical
Phase III
Registrational
Clinical Trial in
Indonesia
Topical Gel
✓ Patient dosing is now underway with
five (5) clinical study sites activated
across Indonesia. Trial designed to
enrol up to 310 patients, assessing
clinical response according to the
Lipsky Scale.
Launch Registrational Phase III
trial for ABSSSI in Australia
Phase III ABSSSI
Clinical Trial
Topical Gel
Phase III Indonesia Interim data
readout Q1 2026 potential
market approval mid 2026
Phase III DFI
Clinical Trial
Topical Gel
Dept. of Defense
Burn Wound
Programs
Topical Gel
Advance across three US Defense
Programs
Trial Data Released
Trial Commenced
2025/2026 Corporate Goals
9
Global Expansion into High-Growth Healthcare Markets
Regulatory approvals in ASEAN, Middle East (MENA region)
Military Partnerships and Grant Funding
Funding, R&D partnerships, licensing, grant submissions
Delivery of Phase 3 Clinical Data
Expected Interim data readout Q1 2026; potential market approval mid 2026
Commercial Partnerships
Advancing clinical evaluation, registration, and potential commercialisation of Recce’s proprietary
anti-infective portfolio
• Patient dosing is now underway with five (5) clinical
study sites activated across Indonesia. Trial designed
to enrol up to 310 patients, assessing clinical response
according to the Lipsky Scale.
• Opportunity to access 10 ASEAN member states –
680 million inhabitant, including 280 million in Indonesia.
• Memorandum of Understanding (MoU) with leading
Indonesian biomedical company PT Etana
Biotechnologies.
10
Phase 3
Registrational
Clinical Trial in
Indonesia
Topical Gel
Recce & Badan POM Team’s - Recce CEO James Graham
(centre left) and Head of Drug and Food Authority Badan POM,
Professor Taruna Ikrar (centre)
Awarded expedited regulatory review status in Indonesia to fast-track progression of Phase 3 trial
Strategic Opportunity in South-East Asia
Opportunity
Presents an
Innovative Path to
Global Access
• Significant bilateral initiative supported by Australian
and Indonesian Governments.
• Expected launch in 2026 in ASEAN region.
• Multiple therapeutics for unmet medical needs
expected to follow such as: tuberculosis, post-op
infections, burn wounds etc.
Registrational Phase III Clinical Trial - Indonesia
11
Title: Phase III, Double-blind, Placebo-Controlled Study of R327 Topical Gel for the Treatment of Diabetic Foot Ulcer Infections
Multi-centre, 5 activated
sites across Indonesia.
Over 20.9 million adults in
Indonesia are living with
diabetes – more than 1 in
every 10 adults.
Up to 310 participants,
participants will be enrolled
who present with a mild
diabetic foot ulcer infection.
Interim data analysis to be
conducted after 155
participants.
Primary Endpoint: Assess the
clinical response of the DFI
according to the Lipsky Scale.
Secondary Endpoints: DFI total
wound score and safety of R327G.
Population
Locations Endpoints
Intervention
Participants to receive either R327
topical gel or placebo topical gel.
Expected Interim data readout Q1 2026; potential market approval mid 2026
Diabetic Foot Infections - Large Addressable Market
12
• Significant near-term opportunity for Recce with registrational Phase 3
trials anticipated to be completed in FY26 paving the way for future
revenues
• Opportunity to access 10 ASEAN member states covering a
population of 670 million inhabitants
• Initially targeting Indonesian market valued at ~US$189 million where
DFI impacts 11% of the population2
US$5.2B
Est. global DFI
treatment
market1
• Indonesian approvals provide access to the broader Asia Pacific
market worth ~US$1.0 billion per year3
• In Indonesia, DFIs are severe resulting in amputation in 46.9% of
hospitalised patients4.
• In-hospital treatment costs averaging USD ~$4,100 per patient and
significantly higher costs for amputees, highlighting the substantial
clinical and economic burden of DFI on the national health system5
US$189M
Est. Indonesian
DFI Market2
Source: (1) Grand View Research, Diabetic Foot Ulcer Treatment Market Size, 2023 (2) Diabetes Atlas, International Diabetic Federation and Prof EM Yunir, Faculty of Medicines,
University of Indonesia. (3) Business Market Insights, Asia Pacific Diabetic Foot Ulcer Market, 2021 (4) Grand View Research, Anti-Infective Agents Market Size, 2023 5.
https://doi.org/10.1016/j.heliyon.2024.e41263
~US$135.4B
Estimated value of the
significant additional
market opportunities in the
broader anti-infectives
market
Recce already exploring
opportunities in burn
wound infections, skin and
soft tissue infections post
operation4
Military Partnerships and Additional Funding
Non-Dilutive Financing via Debt Facility with
Avenue Capital Group
• Debt facility of up to ~A$30m (US$20m) established
with Avenue Capital Group
• Funding to support two Registrational Phase 3
clinical trials in Indonesia and Australia, including
manufacturing, regulatory submissions, and market
launch preparation for R327G.
Canadian Scientific Research & Experimental
Development Rebate
• US$175,122 (A$271,987) from the Canadian
Government received.
13
US Military Engagement
U.S. Department of Defense Burn Wound Program
• U.S. Department of Defense Grants Recce
Pharmaceuticals US$2 million to accelerate
development of R327G for acute treatment of burn
wound infections
Defense Threat Reduction Agency (DTRA) Backed
Cooperative Research & Development Agreement
with United States Army Medical Research Institute
of Infectious Diseases (USAMRIID)
• Testing R327 against highly hazardous pathogens of
biodefense concern in USAMRIID under high
biocontainment conditions.
Non-dilutive Funding
recce.com.au
• This Phase II study achieved all primary and secondary endpoints as an open-label
clinical trial evaluating the safety and tolerability, efficacy, and plasma pharmacokinetics
of R327G when applied directly to the infected area
• The study enrolled 30 patients, with 29 included in the final data analysis. One patient
was withdrawn due to pre-existing pain at the wound site that was deemed unrelated to
R327G
• After 7 days of treatment, 86% of patients (25 out of 29) treated with R327G had a
successful clinical response
• At 14 days of treatment, 93% of patients (27 out of 29) achieved a primary efficacy
endpoint
• R327G demonstrated to be safe and well tolerated, achieving all endpoints - no Serious
Adverse Events reported
Phase II ABSSSI Clinical Trial
Achieved all Endpoints
Study Outcome* To evaluate the efficacy of RECCE®327 topical gel on ABSSSI
Assessment method Lipsky Scale/Bates Jensen Wound Assessment Tool
Endpoint met Yes
*https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=387997&isReview=true
Successful clinical response
86%
93%
After 7 days of treatment
After 14 days of treatment
14
Robust Worldwide Intellectual Property Portfolio
15
Family 1 group relates to the Company’s Unique and
Highly Economical Manufacturing Process and use of the
Polymer in Treatment of Diseases.
Family 2 relates to the Method of Manufacture,
Administration and Application to Treat a Broad Range of
Common Human Infections.
Family 3 relates to a Method of Treatment of a Broad
Range of Viral Infections, particularly Parenteral Viral
Infection.
Family 4 relates to Process for Preparation of
Biologically Active Copolymer, other Patent Cooperation
Treaty countries pending/granted)
Recce’s patent portfolio contains over 40 patents and patent applications in the world’s major markets.
Filed
Patent
Family 1
Expiry
Patent
Family 2
Expiry
Patent
Family 3
Expiry
Patent
Family 4
Expiry
Australia ✓ 2028 ✓ 2037 ✓ 2037 ✓ 2041
USA ✓ 2029 ✓ 2037 ✓ 2037 Pending -
Europe ✓ 2028 ✓ 2037 ✓ 2037 Pending -
Germany ✓ 2028 ✓ 2037 ✓ 2037 - -
Spain ✓ 2028 ✓ 2037 ✓ 2037 - -
France ✓ 2029 ✓ 2037 ✓ 2037 - -
UK ✓ 2028 ✓ 2037 ✓ 2037 - -
Italy ✓ 2028 ✓ 2037 ✓ 2037 - -
Sweden ✓ 2028 ✓ 2037 ✓ 2037 - -
Japan ✓ 2028 ✓ 2037 ✓ 2037 ✓ 2041
China ✓ 2028 ✓ 2037 ✓ 2037 ✓ 2041
HK Pending 2028 Pending 2037 ✓ 2037 Pending -
Israel - - - - - - ✓ 2041
Canada - - - - - - ✓ 2041
Summary
16
Significant value creating opportunities
Novel, Synthetic, Broad-Spectrum,
Rapid-Acting, Anti-Infectives:
demonstrated against >500
clinical isolates including all
resistant species; no signs of
resistance to R327
Indonesian Phase 3 registrational
clinical trial data read-out and
regulatory submission
expected in late 2025, potential
market approval and commercial
launch in H1 2026
Upon completion of Phase 3
registrational clinical trial,
enables Recce to replicate
regulatory approval for
R327G across the broader
ASEAN region
Development of a first new class
of antibiotic in over 40 years, recognised by
the World Health organisation, with accelerated
de-risking via registrational Phase 3 trials in
Indonesia and Australia
Expansion of Recce’s Global
Regulatory Strategy including US IND and
Department of Defense partnership
recce.com.au
Thank you
James Graham
Managing Director and Chief Executive Officer
Recce Pharmaceuticals Ltd
ASX:RCE; FSE:R9Q
17
Share your feedback
Discover